| sleep paralysis | <neurology, physiology> A condition that occurs in REM stage sleep. There is no movement of the skeletal muscles in this stage of sleep. See: REM stage sleep. (27 Sep 1997) |
|---|---|
| sleep phase delay syndrome | <syndrome> A disorder in which the circadian rhythm of sleep and waking falls into a delayed but stable relationship with external time cues of day and night. (05 Mar 2000) |
| sleep spindle | The electroencephalographic record of 14-per-second bursts of wave frequency seen on EEG examination. (05 Mar 2000) |
| sleep stages | Periods of sleep manifested by changes in eeg activity and certain behavioural correlates; includes stage 1: sleep onset, drowsy sleep; stage 2: light sleep; stages 3 and 4: delta sleep, light sleep, deep sleep, telencephalic sleep. (12 Dec 1998) |
| sleep terror | A disorder allied to nightmare, occurring in children, in which the child awakes screaming with fright, the distress persisting for a time during a state of saemiconsciousness. Synonym: pavor nocturnus, sleep terror. (05 Mar 2000) |
| delta sleep-inducing peptide | <chemical> A nonapeptide that is found in neurons, peripheral organs, and plasma. This neuropeptide induces mainly delta sleep in mammals. In addition to sleep, the peptide has been observed to affect electrophysiological activity, neurotransmitter levels in the brain, circadian and locomotor patterns, hormonal levels, psychological performance, and the activity of neuropharmacological drugs including their withdrawal. Chemical name: Delta sleep-inducing peptide (12 Dec 1998) |
| obstructive sleep apnoea | A form of sleep apnoea which occurs as the result of a physical occlusion of the oropharyngeal airway during sleep. (27 Sep 1997) |
| electric sleep | A condition of convulsions and unconsciousness induced by the passage of an electric current through the brain. (05 Mar 2000) |
| electrotherapeutic sleep therapy | Treatment by inducing sleep by means of nonconvulsive electric stimulation of the brain. (05 Mar 2000) |
| twilight sleep | Formerly a method of producing sleep for delivery by a combination of morphine and scopolamine. (05 Mar 2000) |
| light sleep | A condition of half sleep. Synonym: light sleep. Origin: dys-+ G. Nystaxis, drowsiness (05 Mar 2000) |
| abortifacient agents, non-steroidal | Non-steroidal chemical compounds with abortifacient activity. (12 Dec 1998) |
| acute non-lymphocytic leukaemia | <haematology> A form of leukaemia which is characterised by the proliferation of immature bone marrow precursor cells in the marrow and immature white blood cells (granulocytes) in the bloodstream. Occurs primarily in adults and in infants under 1 year of age. Complications include abnormal bleeding and susceptibility to infections. Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains. Trisomy-8 is the most common cytogenetic abnormality observed, followed by monosomy-7 and monosomy-5. Approximately 8% of cases show trisomy-8, mostly in AML (M1), AM (M4) and acute monocytic leukaemia (M5). Many pre-leukaemic conditions, acute non-lymphocytic leukaemia and secondary leukemia show monosomy-7 or deletion of the long arm of chromosome 7. Treatment includes chemotherapy and/or bone marrow transplant. Acronym: ANLL Incidence: 2.5 cases per 100,000 (all ages). Origin: Gr. Haima = blood (07 Apr 1998) |
| analgesics, non-narcotic | Drugs that have principally analgesic, antipyretic, and anti-inflammatory actions. They do not bind to opioid receptors and are not classified under the controlled substances act. (12 Dec 1998) |
| anti-inflammatory agent, non-steroidal | Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain nsaids also may inhibit lipoxygenase enzymes or phospholipase c or may modulate T-cell function. (ama drug evaluations annual, 1994, p 1814-5) (12 Dec 1998) |